An efficient methodology for the preparation of the -tetrasubstituted proline analogue (S,S,S)-2-methyloctahydroindole-2-carboxylic acid, (S,S,S)-( Me)Oic, and its enantiomer, (R,R,R)-( Me)Oic, has been developed. Starting from easily available substrates and through simple transformations, a racemic precursor has been synthesized in excellent yield and further subjected to HPLC resolution using a cellulose-derived chiral stationary phase. Specifically, a semipreparative (250 20 mm ID) Chiralpak ® IC column has allowed the efficient resolution of more than 4 grams of racemate using a mixture of n-hexane/tert-butyl methyl ether/2-propanol as the eluent. Multigram quantities of the target amino acids have been isolated in enantiomerically pure form and suitably protected for incorporation into peptides.
INTRODUCTION
Peptides are mediators of key biological functions in our organism and, thereby, provide a great opportunity for therapeutic applications. However, the use of natural peptides as drugs is strongly limited by their rapid metabolism, low bioavailability and poor receptor subtype selectivity. 1 Therefore, much effort is being devoted to endow peptides with enhanced therapeutic properties.
In this context, the incorporation of constrained -amino acids into peptides constitutes a very useful strategy to reduce their flexibility and retard enzymatic degradation. 1, 2 Moreover, restricted -amino acids stabilize particular conformational features, which may lead to improvements in the biological potency if the bioactive conformation is tethered. 1, 2 In particular, -methylation of -amino acids is an efficient way to produce surrogates with defined conformational preferences. 3 Indeed, the incorporation of -methyl amino acids into peptides has shown to reduce their conformational freedom and to prevent the hydrolytic cleavage of neighboring peptide bonds. has frequently been used as a replacement for proline to control the secondary structure, and hence, the biological behavior of peptides. [6] [7] [8] The great number of patents dealing with bioactive peptides containing ( Me)Pro provides evidence for the enormous value of this amino acid (in general, of -methylated amino acids) in the development of therapeutic agents.
<Figure 1>
Octahydroindole-2-carboxylic acid (Oic, Fig. 1 ) is a proline analogue containing a fused cyclohexane ring that has proven extremely useful to optimize the pharmacological profile of bioactive peptides. Particularly notable has been the use of (S,S,S)-Oic for the design of angiotensin-converting enzyme (ACE) inhibitors, 9 antagonists for the B2 receptor of 4 bradykinin 10, 11 and prolyl oligopeptidase (POP) inhibitors. 12 Such (S,S,S)-Oic-containing compounds are useful, among other applications, as antihypertensive drugs, anti-inflammatory agents, for the prevention of heart failure, or the treatment of neurodegenerative diseases and, in fact, a number of them are already on the market or have entered clinical evaluation.
As the -methylated counterpart of Oic, -methyloctahydroindole-2-carboxylic acid [( Me)Oic, In spite of its great potential value, the behavior of ( Me)Oic when included into peptides or other biologically relevant systems remains unexplored. This is due to the lack of synthetic methodologies providing access to the different stereoisomers of ( Me)Oic in enantiomerically pure form. In fact, at variance with Oic, attention on the -methylated counterpart ( Me)Oic has been focused only recently. Within this context, we have described the preparation of enantiopure (S,S,S)-( Me)Oic 13 and its epimer at the carbon (R,S,S)-( Me)Oic 14 by means of stereoselective alkylation processes. To the best of our knowledge, these are, together with the preparation of (S,S,S)-( Me)Oic described in a patent, 15 the only synthetic routes to ( Me)Oic 5 reported to date. Therefore, development of efficient methodologies that ensure accessibility to these and other ( Me)Oic stereoisomers, in optically pure form and significant quantities, remains a challenge. We describe here a convenient route for the multigram-scale preparation of both (S,S,S)-( Me)Oic and (R,R,R)-( Me)Oic in enantiomerically pure form. The procedure combines the synthesis of a racemic precursor and a chromatographic resolution procedure.
MATERIALS AND METHODS

General
All reagents from commercial suppliers were used without further purification. Thin-layer chromatography (TLC) was performed on Macherey-Nagel Polygram syl G/UV precoated silica gel polyester plates. The products were visualized by exposure to UV light (254 nm), iodine vapour or submersion in cerium molybdate stain [aqueous solution of phosphomolybdic acid (2%), CeSO 4 ·4H 2 O (1%) and H 2 SO 4 (6%)]. Column chromatography was performed using
Macherey-Nagel 60Å silica gel. Melting points were determined on a Gallenkamp apparatus and are uncorrected. IR spectra were registered on a Mattson Genesis or a Nicolet Avatar 360 FTIR spectrophotometer; max is given for the main absorption bands. 1 H and 13 C NMR spectra were recorded on a Bruker AV-400 instrument at room temperature using the residual solvent signal as the internal standard; chemical shifts ( ) are expressed in ppm and coupling constants (J) in
Hertz. Optical rotations were measured at room temperature using a JASCO P-1020 polarimeter.
High-resolution mass spectra were obtained on a Bruker Microtof-Q spectrometer.
High-Performance Liquid Chromatography
HPLC was carried out using a Waters 600 HPLC system equipped with a 2996 photodiode array detector and a 2487 dual wavelength absorbance detector (respectively used for monitoring analytical and preparative separations 2) are their retention times, and w 1 and w 2 denote their half-height peak widths; t 0 is the dead time.
X-ray diffraction
Colorless single crystals of racemic (S*,S*,S*)-10 were obtained by slow evaporation from a dichloromethane/ethyl acetate solution. The X-ray diffraction data were collected at 100K on an Oxford Diffraction Xcalibur diffractometer provided with a Sapphire CCD detector, using graphite-monochromated Mo-K radiation ( = 0.71073 Å). The structure was solved by direct methods using SHELXS-97 16 and refinement was performed using SHELXL-97 17 Crystallographic data: orthorhombic, space group Pbca; a = 7.5997 (2) those reported in our previous work 13 for the (S,S,S) enantiomer.
Synthesis of methyl (2S
Synthesis of methyl (2S*,3aS*,7aS*)-N-(benzyloxycarbonyl)-2-methyloctahydroindole-2-carboxylate [(S*,S*,S*)-11].
To an ice-cooled solution of (S*,S*,S*)-10 (3.42 g, 14.63 mmol)
and N,N-diisopropylethylamine (10.4 ml, 59.68 mmol) in dry dichloromethane (75 ml), benzyl chloroformate (4.40 ml, 29.28 mmol) was added dropwise. Once the addition was completed, the reaction was kept at room temperature overnight. The mixture was washed with saturated aqueous NaHCO 3 , and the organic phase was dried over anhydrous MgSO 4 and filtered. The solvent was evaporated and the residue was purified by column chromatography (eluent:
hexanes/ethyl acetate 10/1) to give (S*,S*,S*)-11 as a colorless oil (4.47 g, 13.49 mmol, 92% yield 
Synthesis of (2R,3aR,7aR)-N-(benzyloxycarbonyl)-2-methyloctahydroindole-2-carboxylic acid [(R,R,R)-12].
An identical procedure to that described above was applied to transform Spectroscopic data are the same as those described for (S,S,S)-12.
RESULTS AND DISCUSSION
Synthesis of a racemic precursor
The first stage in the synthesis of enantiomerically pure (S,S,S)-and (R,R,R)-( Me)Oic involved the preparation of a racemic common precursor to be subsequently subjected to HPLC resolution.
The synthesis of such a precursor was addressed by modification of the asymmetric route previously reported 13 for the preparation of enantiopure (S,S,S)-( Me)Oic, which is presented in The racemic version of this methodology would require the use of racemic indoline-2-carboxylic acid (rac-1) as a substrate (Fig. 3) . Alternatively, the completely unsaturated compound, indole-2-carboxylic acid (8) (Fig. 3) , can be envisaged as a less expensive starting material for the preparation of the racemate (S*,S*,S*)-4. However, according to the literature, 18, 19 the catalytic hydrogenation of the indole system requires harsh reaction conditions (high temperatures and pressures of hydrogen gas). Yet, some ester derivatives of 8 have been reported 20 to undergo hydrogenation under Rh/C catalysis and hydrogen pressure at room temperature.
<Figure 3>
Based on this precedent, we undertook the preparation of the target amino acids, (S,S,S)-and (R,R,R)-( Me)Oic, starting from an adequately protected derivative of indole-2-carboxylic acid (8) , namely the N-Boc protected ester 9 (Fig. 3) . The latter compound was readily obtained by reaction of 8 with methanol in the presence of sulfuric acid followed by treatment with di-tertbutyl dicarbonate. The hydrogenation of 9 using PtO 2 as a catalyst was accomplished at room temperature and atmospheric pressure of hydrogen gas. It seems, therefore, that both the amino 13 and carboxylic acid functions in 8 are to be in the protected form (as are in 9) for the hydrogenation of the indole system to proceed under such mild conditions. The choice of PtO 2 as the catalyst for this reaction was based on our previous observation 13 that the aromatic ring in (S)-1 is efficiently hydrogenated at atmospheric pressure in the presence of PtO 2 (Fig. 2) , whereas the use of Pd/C or Rh requires high pressure of hydrogen. 21, 22 Moreover, we were delighted to observe that the hydrogenation of 9 provided racemic (S*,S*,S*)-4 as a single product. This differential behavior with respect to that described above for (S)-1 ( Fig. 2) is due to the fact the three chiral centers are formed at once upon hydrogenation of 9 (Fig. 3) . Accordingly, only the compound exhibiting a cis relative disposition of the two bridgehead hydrogen atoms and that at the position, (S*,S*,S*)-4, is obtained in this process.
Therefore, the route in Fig. 3 constitutes a highly efficient manner to access racemic (S*,S*,S*)-4
as a single stereoisomer in high overall yield (88%) starting from inexpensive indole-2-carboxylic acid (8) . Certainly, this route is much more convenient for the production of racemic Oic derivatives exhibiting an (S*,S*,S*) relative stereochemistry than the racemic version of the asymmetric synthesis reported before 13 ( Fig. 2) , that would require the use of indoline-2-carboxylic acid (rac-1) as a substrate. As outlined above, the procedure in Fig. 3 is more advantageous in terms of accessibility of the starting material (8 is substantially cheaper than rac-1), global yield, hydrogenation conditions (the process in Fig. 2 requires heating at 60 ºC), and stereoselectivity of the hydrogenation process (complete vs 90:10). The synthetic pathway in Fig.   3 is therefore highly convenient for the production of (S*,S*,S*)-Oic derivatives on a large scale.
Once racemic (S*,S*,S*)-4 was obtained according to the procedure in Fig. 3 , the synthetic route proceeded in a similar way to that described in the asymmetric version previously reported 13 and shown in Fig. 2 . Thus, the treatment of (S*,S*,S*)-4 with lithium diisopropylamide generated an intermediate lithium enolate that reacted with methyl iodide to provide an 89:11 mixture of the 14 two possible diastereoisomers, (S*,S*,S*)-5 and (R*,S*,S*)-6 (Fig. 4) . It should be noted that the high steric hindrance imposed by the cis-fused cyclohexane ring was responsible for the efficient facial stereodifferentiation observed. 13 The major diastereoisomer, (S*,S*,S*)-5, was isolated pure from the crude mixture by column chromatography in 75% yield.
<Figure 4>
At this stage, we undertook the exchange of the N-Boc protecting group by the Cbz one, as the latter has the advantage of absorbing in the UV range, thus favoring monitoring of the subsequent chromatographic resolution process. This was achieved by treatment of (S*,S*,S*)-5 with a saturated solution of hydrogen chloride in ethyl acetate followed by reaction with benzyl chloroformate (Fig. 4) . In this way, several grams of (S*,S*,S*)-11 were prepared in 61% overall yield from indole-2-carboxylic acid (8) . The intermediate amino ester hydrochloride, (S*,S*,S*)-10, furnished single crystals suitable for X-ray diffraction analysis. The crystalline structure (Fig.   5 ) confirmed the expected (S*,S*,S*) relative stereochemistry. As shown in Fig. 5 , the cyclohexane ring adopts a chair conformation, which is slightly distorted to accommodate the cisfused five-membered cycle. The latter exhibits an envelope shape, with one of the carbon atoms involved in the fusion (3a) occupying the flap of the envelope. It should be noted that inversion of the reactions sequence carried out to transform (S*,S*,S*)-4 into (S*,S*,S*)-11 was examined, but only poor results were obtained. Thus, when the Cbz group was introduced in (S*,S*,S*)-4 prior to the -methylation reaction, the latter process afforded only a 25% yield of (S*,S*,S*)-11
( Fig. 4) . Accordingly, this alternative pathway was discarded.
<Figure 5>
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HPLC resolution: Isolation of enantiopure amino acids
Once the racemic precursor of the target amino acids, (S*,S*,S*)-11, had been obtained, we addressed its resolution by HPLC. The separation of enantiomers by preparative chromatography using chiral stationary phases is nowadays recognized as a powerful tool to produce enantiopure compounds. [23] [24] [25] Polysaccharide-based stationary phases are particularly suitable for this purpose due to their excellent chiral recognition ability and high loading capacity. [23] [24] [25] Moreover, HPLC columns containing immobilized cellulose and amylose derivatives have recently become commercially available (Chiralpak ® IA, IB, and IC). [26] [27] [28] In these columns, the chiral support is covalently bonded to the silica matrix, which results in a high stability in the presence of all organic solvents. [25] [26] [27] [28] [29] This feature means a great advantage for resolutions on a preparative scale.
Chiral stationary phases of this type, either commercial or made at the laboratory (prior to their commercialization), have been used in our group for the preparative HPLC resolution of a wide variety of non-natural protected amino acids.
30-41
The resolution of racemic (S*,S*,S*)-11 was firstly tested at the analytical level using 250 4.6 mm Chiralpak ® IA, IB, and IC columns, that respectively contain tris (3,5- dimethylphenylcarbamate) of amylose, 26 tris(3,5-dimethylphenylcarbamate) of cellulose, 27 and tris(3,5-dichlorophenylcarbamate) of cellulose as the chiral selector. 28 The screening started using mixtures of n-hexane/2-propanol as the eluent. The enantiomers of 11 could not be distinguished on the IA column, whereas both Chiralpak ® IB and IC showed excellent enantiodiscrimination abilities, with selectivity factors around 1.6 (Table 1) . Replacement of the alcohol component in the eluting mixture by acetone was next tested. This change had little effect for the cellulosebased phases, whereas very much improved the chiral recognition ability of Chiralpak ® IA. In fact, an almost complete baseline separation of peaks was achieved when eluting with nhexane/acetone 96/4 (v/v) on this stationary phase (Table 1 ). In spite of this, it remained much 16 less effective that the cellulose-derived ones and was therefore not considered for further assays.
The addition of a third component to the initial n-hexane/2-propanol mixture was then evaluated.
Among those tested, tert-butyl methyl ether provided the best results, particularly for the IC column (Table 1) . Thus, when working on this stationary phase, the presence of a high percentage of this solvent in the mobile phase not only improved the selectivity but also led to a substantial enhancement of the resolution factor. Moreover, this change also resulted beneficial to the sample solubility, which is an extremely important issue for the subsequent scaling-up stage.
Accordingly, the analytical conditions considered to be optimal for extension to the preparative- These conditions were subsequently scaled-up for the preparative resolution of (S*,S*,S*)-11 on a 250 20 mm ID Chiralpak ® IC column. Successive injections of 600 l of a highly concentrated solution of the sample in chloroform (600 mg per ml of solvent) were performed (Fig. 7) . Each run was collected into three separate fractions according to the cut points indicated in Fig. 7 , with equivalent fractions of successive injections being combined. Following this protocol, a total of 4.14 g of racemate were submitted to the resolution procedure, which was completed in about 3
h. Evaporation of the first and third fractions provided 2.04 and 2.01 g of the first and second eluted enantiomers, respectively, both of them in optically pure form, as assessed at the analytical level (Fig. 8) . This means that 98% of the injected material was recovered in enantiomerically 17 pure form after a single passage through the column. The high productivity of the enantioseparation process is therefore remarkable since more than 1 g of optically pure material was isolated per hour working on a semi-preparative size column.
< Figure 7> <Figure 8>
The absolute configuration of the isolated enantiomers was assigned by comparison of their retention times with that of a sample of enantiomerically pure (S,S,S)-11 prepared separately.
Thus, a small amount of (S,S,S)-5 obtained from (S)-indoline-2-carboxylic acid in our previous work 13 following the synthetic procedure in Fig. 2 was transformed into (S,S,S)-11 by exchange of the Boc-Cbz N-protecting groups, and its retention time was found to be coincident with that of the first eluted enantiomer of 11 (Fig. 8) . Accordingly, the more strongly retained enantiomer of 11 was assigned an (R,R,R) configuration.
Finally, each enantiomer of 11 was subjected to saponification to provide the corresponding NCbz amino acid in almost quantitative yield (Fig. 9) . Thus, the target compounds, (S,S,S)-and 
